Alpha memo: resveratrol exercise cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either obtain complete numeric outcomes from both abstracts/full texts, or explicitly downgrade the signal to 'title-level cross-context divergence whose numeric magnitude is unverified,' and remove any reference to specific percentages.
2. Clarify in the one-sentence alpha that the 'split' is between endpoints (inflammation markers in rats vs vascular training adaptations in aged men), not a direct anti-inflammatory vs blunting contrast on the same outcome.
3. Add a short sentence on why Receipt 1's inflammation endpoints (IL-6) and Receipt 2's vascular endpoints (VO2max, leg hemodynamics) are not directly comparable, reinforcing that this is a heterogeneous evidence map rather than a mechanistic contradiction.
4. Tighten the falsifier: specify that a decisive falsifier would be a human RCT at 250 mg resveratrol showing additive benefit on VO2max or the same vascular endpoint, not generically 'synergistic' effects.

Major issues

• The memo hinges on a cross-context contrast (rodent anti-inflammatory plausibility vs human RCT blunting effect) but neither receipt's abstract provides complete numeric endpoints. The '45% figure' mentioned in caveats is never substantiated or used in the signal, and the memo explicitly admits abstracts are truncated, leaving the central comparison unverified.
• Receipt 1 is about acute exercise-induced inflammation in rats; Receipt 2 is about vascular training responses (leg hemodynamics, VO2max) in aged men. The 'split' the memo highlights (anti-inflammatory vs blunted benefit) conflates different endpoints and different mechanistic levels, which weakens the bounded signal claim.

Minor issues

• Title/source alignment is acceptable: resveratrol + exercise is the shared anchor in both receipts, and the cross-context contrast (rat vs aged human men) is explicit.
• The one-sentence alpha could more clearly state what is 'surprising' is a species/population discrepancy, not a within-compound contradiction.
• The falsifier framing is good but could specify which vascular endpoint (VO2max, leg hemodynamics) would need to replicate.

Reviewer note

The memo correctly identifies a legitimate cross-context contrast in the resveratrol + exercise literature: a rodent study framing resveratrol as plausibly anti-inflammatory during exercise vs a human RCT whose title claims resveratrol blunts training benefits. The title/source alignment is sound—both receipts concern resveratrol with exercise—and the limitations section is honest about species, population, dose, and duration differences, and about truncated abstracts preventing numeric verification. However, the central signal is weaker than presented. Receipt 1 measures inflammation-related factors (IL-6 framed) in rats after acute exercise; Receipt 2 measures vascular training responses (VO2max, leg hemodynamics) in aged men. The memo implicitly treats these as comparable endpoints, but they are mechanistically and clinically distinct. The 'split' is therefore partly an artifact of endpoint heterogeneity rather than a clean species-level contradiction. Additionally, both abstracts are truncated, so the memo cannot verify either effect's direction or magnitude—it can only lean on the RCT's title claim. The stray '45% figure' reference in caveats is never used and never sourced, which is a minor cleanliness issue. This is a competent but fixable alpha memo. The structural skeleton is correct, the caveats are appropriately hedged, and the falsifier is reasonably specified. But the bounded signal needs to either be downgraded (explicitly acknowledging the endpoints are non-comparable and only the title-level contrast is supported) or strengthened with complete source data. Recommend revise with bounded edits to clarify endpoint heterogeneity and remove the unsupported percentage reference.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis